Adam Walkerprofile image
Dr

Adam Walker


Current Appointments

Research Fellow, Group Leader - Laboratory of Immunopsychiatry, Neuroscience Research Australia
Senior Researcher, UNSW, School of Psychiatry
email hidden; JavaScript is required

The Laboratory of ImmunoPsychiatry, led by Dr Adam Walker, investigates the role of the immune system and inflammation in symptoms of psychiatric illness. We investigate the mechanisms responsible for inflammation-associated psychiatric disorders such as depression and schizophrenia, neurodevelopmental disorders such as Tourette’s Syndrome and Autism, and when symptoms of depression and cognitive impairment occur in patients with chronic inflammatory illness such as cancer (known as ‘chemobrain’). The Laboratory of ImmunoPsychiatry is dedicated to identifying potential cheap available drugs that can be repurposed to prevent and treat psychiatric illness and to identify new biological targets for novel drug design.

Dr Adam Walker completed his PhD at the University of Newcastle in 2011 and completed successful postdoctoral fellowships at the University of Illinois – Urbana-Champaign and The University of Texas MD Anderson Cancer Center.  He returned to Australia in 2015 and joined Monash University as a National Breast Cancer Foundation research fellow, investigating the mechanisms underlying cognitive and psychiatric side-effects of cancer and its treatment. Now at NeuRA, Adam’s research focuses on mechanisms of inflammation-induced depression, schizophrenia and cancer-associated cognitive impairment. He has pioneered discovery of available drugs that may be repurposed to prevent treat inflammation-induced depression (ketamine, leucine) and cancer-associated cognitive impairment (aspirin).


Publications

2023, 24 Aug

Immp2l knockdown in male mice increases stimulus-driven instrumental behaviour but does not alter goal-directed learning or neuron density in cortico-striatal circuits in a model of Tourette syndrome and autism spectrum disorder

View full journal-article on https://app.dimensions.ai/details/publication/pub.1162934469

2023 Aug

Antioxidant Behavioural Phenotype in the <i>Immp2l</i> Gene Knock-Out Mouse

View full journal-article on https://www.mdpi.com/2073-4425/14/9/1717

2023, 01 Jul

Changes in cytokine and cytokine receptor levels during postnatal development of the human dorsolateral prefrontal cortex

View full journal-article on https://app.dimensions.ai/details/publication/pub.1156378812

2023, 01 Jul

Increased prefrontal cortical cells positive for macrophage/microglial marker CD163 along blood vessels characterizes a neuropathology of neuroinflammatory schizophrenia

View full journal-article on https://app.dimensions.ai/details/publication/pub.1156492860

2023, 01 Apr

receiving endocrine therapy: what are the impacts?

View full journal-article on https://app.dimensions.ai/details/publication/pub.1156496810

2023, 01 Jan

Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer

View full journal-article on https://app.dimensions.ai/details/publication/pub.1157546268

2022, 01 Dec

Cancer activates microglia to the same extent as chronic stress throughout stress neurocircuitry in a mouse model of breast cancer

View full journal-article on https://app.dimensions.ai/details/publication/pub.1151187166

2022, 01 Dec

NSAID use and unnatural deaths after cancer diagnosis: a nationwide cohort study in Sweden

View full journal-article on https://app.dimensions.ai/details/publication/pub.1144737346

2022, 01 Dec

Peripheral NF-κB dysregulation in people with schizophrenia drives inflammation: putative anti-inflammatory functions of NF-κB kinases

View full journal-article on https://app.dimensions.ai/details/publication/pub.1144619749

2022, 01 Oct

Dietary intake in children on the autism spectrum is altered and linked to differences in autistic traits and sensory processing styles

View full journal-article on https://app.dimensions.ai/details/publication/pub.1150506759